58 results about "Potassium Clavulanate" patented technology

The invention discloses an amoxicillin potassium clavulanate powder injection which is prepared from the following raw materials in percentage by weight: 10% of amoxicillin, 2.5% of potassium clavulanate, 4% of cosolvent and the balance of soluble filler. The invention also discloses a preparation method of the amoxicillin potassium clavulanate powder injection. The test proves that the amoxicillin potassium clavulanate powder injection disclosed by the invention has the characteristics of stability in storage, convenience in transportation, good water solubility and the like and greatly improves the curative effect of the amoxicillin and potassium clavulanate, thereby being a novel broad-spectrum and efficient special powder injection for animals.

The invention discloses an amoxicillin / potassium clavulanate sustained-release preparation composition and a preparation method thereof. The compound is mainly prepared from amoxicillin, potassium clavulanate, sustained-release materials and other appropriate accessories. The amoxicillin / potassium clavulanate sustained-release preparation provided by the invention can delay the release speed of a main drug, reduce the times of taking the medicine and improve the compliance of a patient. The amoxicillin / potassium clavulanate sustained-release preparation composition provided by the invention has quality controllability and quality and good stability of the of preparation process.

The invention discloses an amoxicillin sodium potassium clavulanate composition microballoon injection, which is characterized by comprising the following components in parts by weight: 5 parts of amoxicillin sodium, 1 part of potassium clavulanate, 4-6 parts of gelatin, 4-6 parts of Arabic gum, 3-6 parts of disodium hydrogen phosphate, 2-4 parts of trehalose and 1-3 parts of glycerol. Compared with the prior art, the amoxicillin sodium potassium clavulanate composition microballoon injection prepared by the invention has good stability, high entrapment rate, good process repeatability, even particle distribution, good injectable property and good slow release character, and is suitable for industrialization production.

The invention discloses amoxicillin potassium clavulanate dry suspension and a production process thereof. The amoxicillin potassium clavulanate dry suspension is prepared from amoxicillin, potassium clavulanate, hydroxy propyl methylcellulose and the like in a mixing manner. The amoxicillin potassium clavulanate dry suspension has good compliance to a user.

The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.

Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

The invention belongs to the technical field of western medicine preparations, and particularly relates to a dispersible tablet containing amoxicillin and potassium clavulanate. The dispersible tablet comprises the following components in parts by weight: 420 parts of amoxicillin, 60 parts of potassium clavulanate, 350-400 parts of filler, 80-100 parts of low-substituted hydroxypropyl cellulose, 1-20 parts of colloidal silicon dioxide and 5-8 parts of magnesium stearate. For the dispersible tablet, both the dispersing uniformity and dissolution achieve the technological effects of the existing product, simultaneously, and the hardness of the pressed tablet is within 50-70N, so that the problems of insufficient hardness and difficulty in common packaging existing in products on the market are solved.

A powder injection for treating bacterium-infectious diseases is prepared from cefoperazone sodium and potassium clavulanate in weight ratio of (1-16):1.

The invention belongs to the technical field of breeding of bamboo rats, and in particular discloses a medicine for preventing and treating enterogastritis in bamboo rats and a preparation method of the medicine. The medicine for preventing and treating enterogastritis in the bamboo rats is mainly prepared by the following materials through baking, extracting, mixing and drying: 10-15 parts of bentonite, 5-9 parts of silicon dioxide, 2-5 parts of sulfaguanidine, 1-5 parts of potassium clavulanate, 1-3 parts of a yeast, 5-10 parts of cherokee rose fruit, 3-8 parts of tea leaves, 3-8 parts of fructus crataegi, 2-8 parts of flos chrysanthemi and 1-5 parts of herba patriniae. The medicine for preventing and treating enterogastritis in bamboo rats provided by the invention, in accordance with principles of cooperative matching and assistant matching, combines chemical medicines and natural Chinese herbal medicines; the medicine mainly functions as diminishing inflammation and killing bacteria, clearing way heat and toxic materials, assisted by effects of clearing intestines and checking diarrhea; the medicine can be used for effectively preventing and treating the enterogastritis in bamboo rats and bring about benefits for healthy growth of the bamboo rats; in addition, the preparation method is simple; and various raw materials can be effectively combined.

The invention discloses an amoxicillin potassium clavulanate tablet. In the tablet, the weight ratio of amoxicillin and potassium clavulanate is 4-8:1. The tablet is formed by even mixing of medicated granules, the potassium clavulanate, a disintegrating agent and a lubricating agent in a direct tablet compressing mode, wherein the disintegrating agent is dried to have the moisture content lower than 3%. The medicated granules comprise amoxicillin and tartaric acid, wherein the weight ratio of the amoxicillin and the tartaric acid is 1:0.1-0.5. The tablet is rapid in dissolution, good in stability, few in auxiliary material kind and simple in preparation technology.

The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or ClavitesseTM, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.

The invention discloses a preparing method of cefodizime sodium for injection, wherein the method comprises the following steps of adding cefodizime sodium to water to obtain the first solution after stirring and dissolving; adding citric acid and potassium clavulanate to the first solution to obtain a second solution after it is completely stirred and dissolved; Adjusting the pH of the second solution to 6.4-6. 6 to obtain a third solution; adding hydroxypropyl Beta-cyclodextrin to the third solution, heating to 53-58 oC, stirring and mixing for 1-2 hours, and cooling to room temperature to obtain a fourth solution; adding the activated carbon with the total weight of 1-2% to the fourth solution, stirring and mixing for 20-30min, and removing the activated carbon by coarse filtration to obtain a fifth solution; The fifth solution is filtered through a microporous membrane to obtain an injecta; freeze-drying the injecta to the powder; the preparing of cefodizime sodium for injection enjoys good stability, and the preparing method is simple, safe and reliable, suitable for clinical use, and industrial production can be carried out on a large scale, with a wide range of applications.